Niagen Bioscience (NAGE) Raw Materials (2018 - 2019)
Niagen Bioscience (NAGE) posted quarterly Raw Materials of $1.4 million for Q4 2019, down 39.49% year-over-year from $2.3 million in Q4 2018, and down 39.49% quarter-over-quarter from $2.3 million in Q4 2018.
Powered by 
Analysis
Niagen Bioscience (NAGE) Raw Materials (2018 - 2019) Analysis & Trends
Niagen Bioscience (NAGE) has reported Raw Materials for 2 consecutive years, with $1.4 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Raw Materials fell 39.49% year-over-year to $1.4 million; the TTM figure through Dec 2019 stood at $1.4 million (down 39.49% YoY), while the FY2019 annual figure was $1.4 million, down 39.49% from the prior year.
- Raw Materials slipped to $1.4 million in Q4 2019 per NAGE's latest filing, from $2.3 million in the prior quarter.
- Across five years, Raw Materials topped out at $2.3 million in Q4 2018 and bottomed at $1.4 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn |